Taro’s Keveyis gets FDA approval

HAWTHORNE, N.Y. — Taro Pharmaceutical Industries announced Monday that its drug Keveyis (dichlorphenamide) had been approved by the Food and Drug Administration. The 50-mg tablets are intended to treat primary hyperkalemic and hypokalemic periodic paralysis.

“The approval of Keveyis demonstrates the importance of industry, scientific researchers, patient advocates and the FDA working together to identify and bring to market a treatment for primary periodic paralysis,” Taro CEO Kal Sundaram said. “We thank the FDA for their continued partnership in making this important day a reality.”

In order to ensure that patients receive treatment for periodic paralysis, Taro will be partnering with Diplomat Pharmacy, where patients and caregivers will receive treatment access and support. Taro has also launched its Keys2Care patient support program, which will ensure patients can begin treatment once diagnosed.

Taro expects Keveyis to become available in the third quarter of 2015.